Literature DB >> 2251874

Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza.

S Tamura1, H Funato, Y Hirabayashi, K Kikuta, Y Suzuki, T Nagamine, C Aizawa, M Nakagawa, T Kurata.   

Abstract

Intranasal inoculation of haemagglutinin (HA) purified from influenza virus A/PR/8/34 (PR8, H1N1) together with cholera toxin B subunit, into Balb/c mice resulted in complete protection against PR8 infection in parallel with the induction of high levels of HA-specific IgA and IgG antibodies on the respiratory tract. The respiratory tract IgA and IgG were purified from nasal and lung washings of the immunized mice using affinity columns, and their HA-specific activities were measured by enzyme-linked immunosolvent, plaque neutralization and haemagglutination inhibition assays. The purified IgA and IgG had the following properties: (1) They were able to neutralize virus in vitro. (2) The purified IgA included major antibodies directed against PR8 virus and minor antibodies cross-reactive with A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) virus, while the purified IgG included major antibodies to the homotypic virus, minor antibodies to the H1N1 virus and only a trace amount of antibodies to the H3N2 virus. (3) When separated on a Sephacryl column, most of the IgA anti-HA activities occurred in the polymeric fractions of purified IgA, whereas the IgG anti-HA activities occurred in the monomeric fractions. (4) When passively administered to normal mouse respiratory tract before infection, the purified IgA protected against PR8 infection. These results suggest that HA-specific, polymeric IgA antibodies on the respiratory tract by themselves provide not only protection against the homotypic virus but also higher levels of heterotypic immunity than IgG.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251874     DOI: 10.1016/0264-410x(90)90250-p

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids.

Authors:  Sari H Pakkanen; Jussi M Kantele; Zina Moldoveanu; Spencer Hedges; Miikka Häkkinen; Jiri Mestecky; Anu Kantele
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

2.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Authors:  Yoshihiko Terauchi; Kaori Sano; Akira Ainai; Shinji Saito; Yuki Taga; Kiyoko Ogawa-Goto; Shin-Ichi Tamura; Takato Odagiri; Masato Tashiro; Mikiya Fujieda; Tadaki Suzuki; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

4.  Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

Authors:  Diana I Albu; Agnes Jones-Trower; Amy M Woron; Kathleen Stellrecht; Christopher C Broder; Dennis W Metzger
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.

Authors:  Lea Torrieri-Dramard; Bénédicte Lambrecht; Helena Lage Ferreira; Thierry Van den Berg; David Klatzmann; Bertrand Bellier
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

6.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

7.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Authors:  Subash C Das; Masato Hatta; Peter R Wilker; Andrzej Myc; Tarek Hamouda; Gabrielle Neumann; James R Baker; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2012-09-16       Impact factor: 3.641

9.  The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin.

Authors:  D M Justewicz; P C Doherty; R G Webster
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.

Authors:  T M Chambers; M Quinlivan; T Sturgill; A Cullinane; D W Horohov; D Zamarin; S Arkins; A García-Sastre; P Palese
Journal:  Equine Vet J       Date:  2009-01       Impact factor: 2.888

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.